RxDoctor Payments Data

Benjamin McDonald

Family Medicine · Foley, ALNPI 1316408263

Payments from drug & device makers

$340in general payments, 2019–2025

Across 20 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$158
  • AstraZeneca$54
  • AbbVie$43
  • Amgen$21
  • GSK$18
  • Lilly USA, LLC$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk9$158
AstraZeneca3$54
AbbVie3$43
Amgen1$21
GSK1$18
Lilly USA, LLC1$17
Mylan Specialty L.p.1$14
Pfizer1$14

How this compares

$340 in reported general payments places this provider in the 40th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$130,755
Medicare patients
428
Services billed
3,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide92$104,835
EliquisApixaban39$49,659
OzempicSemaglutide24$29,718
JardianceEmpagliflozin13$16,814
FarxigaDapagliflozin Propanediol16$15,905
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,315
Praluent PenAlirocumab11$5,313
Albuterol Sulfate HfaAlbuterol Sulfate77$2,523
Duloxetine Hcl37$2,065
Atorvastatin Calcium126$1,712
Omeprazole72$1,596
PaxlovidNirmatrelvir/Ritonavir17$1,429
Bupropion XlBupropion Hcl41$1,237
Rosuvastatin Calcium75$1,184
Levothyroxine Sodium107$1,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$17$104,83592 claims
PfizerEliquis, Paxlovid$14$51,08956 claims
Novo NordiskOzempic$158$29,71824 claims
AstraZenecaFarxiga$54$15,90516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →